Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Recruiting now · Not applicable
Conditions studied: Pancreatic Cancer, Adjuvant Therapy
In brief
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Key facts
- Study ID
- NCT06361316
- Run by
- Kuirong Jiang
- People needed
- 53
- Starts
- 2024-04-08
- Expected to finish
- 2028-07-31
- Last updated by the study team
- 2024-04-11
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ECOG performance status 0 or 1.
- Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
- ECOG performance status 0 or 1.
- Life expectancy of greater than or equal to 6 months.
- Able and willing to provide a written informed consent.
You may not qualify if…
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
Where it is running
- FirstNanjingMU — Nanjing, Jiangsu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.